Intellia Therapeutics says lonvoguran ziclumeran remains effective four years after treatment. The therapy uses CRISPR-Cas9 inside the body to disable the liver gene producing prekallikrein, aiming to prevent painful, potentially dangerous swelling caused by a genetic disorder.